Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels

This article was originally published in PharmAsia News

Executive Summary

While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.

You may also be interested in...



Drug Reimbursement, Biologics Exclusivity Should Be Part Of EU Trade Talks, PhRMA And BIO Say

Branded drug industry representatives presented a number of recommendations for U.S. negotiating priorities in upcoming trade talks with the European Union at a May 30 public hearing.

Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report

The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Topics

Related Companies

UsernamePublicRestriction

Register

SC084630

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel